Search Results - "Arijs, I."

Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity by Vanderbeke, L., Van Mol, P., Van Herck, Y., De Smet, F., Humblet-Baron, S., Martinod, K., Antoranz, A., Arijs, I., Boeckx, B., Bosisio, F. M., Casaer, M., Dauwe, D., De Wever, W., Dooms, C., Dreesen, E., Emmaneel, A., Filtjens, J., Gouwy, M., Gunst, J., Hermans, G., Jansen, S., Lagrou, K., Liston, A., Lorent, N., Meersseman, P., Mercier, T., Neyts, J., Odent, J., Panovska, D., Penttila, P. A., Pollet, E., Proost, P., Qian, J., Quintelier, K., Raes, J., Rex, S., Saeys, Y., Sprooten, J., Tejpar, S., Testelmans, D., Thevissen, K., Van Buyten, T., Vandenhaute, J., Van Gassen, S., Velásquez Pereira, L. C., Vos, R., Weynand, B., Wilmer, A., Yserbyt, J., Garg, A. D., Matthys, P., Wouters, C., Lambrechts, D., Wauters, E., Wauters, J.

“…Epidemiological and clinical reports indicate that SARS-CoV-2 virulence hinges upon the triggering of an aberrant host immune response, more so than on direct…”
Get full text

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis by Arijs, I, Li, K, Toedter, G, Quintens, R, Van Lommel, L, Van Steen, K, Leemans, P, De Hertogh, G, Lemaire, K, Ferrante, M, Schnitzler, F, Thorrez, L, Ma, K, Song, X-Y R, Marano, C, Van Assche, G, Vermeire, S, Geboes, K, Schuit, F, Baribaud, F, Rutgeerts, P

“…Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism…”
Get more information

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort by Schnitzler, F, Fidder, H, Ferrante, M, Noman, M, Arijs, I, Van Assche, G, Hoffman, I, Van Steen, K, Vermeire, S, Rutgeerts, P

“…This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre…”
Get more information

Antimicrobial Prophylaxis in Transurethral Resection of the Prostate: Results of a Randomized Trial by Baten, E, Van Der Aa, F, Goethuys, H, Slabbaert, K, Arijs, I, van Renterghem, K

“…We sought to determine whether omitting antimicrobial prophylaxis is safe in patients undergoing transurethral resection of the prostate without preoperative…”
Get full text

A randomized trial regarding antimicrobial prophylaxis (AMP) in transurethral resection of bladder tumor (TURB) by Baten, E., Van der Aa, F., Goethuys, H., Slabbert, K., Arijs, I., van Renterghem, K.

“…Purpose To determine whether omitting antimicrobial prophylaxis (AMP) in TURB is safe in patients undergoing TURB without an indwelling pre-operative…”
Get full text

Antibiotic prophylaxis in TURP: a prospective analysis concerning antibiotic stewardship and a potential reduction of antibiotic use in TURP by Baten, E., Van Der Aa, F., Orye, C., Cartuyvels, R., Arijs, I., van Renterghem, K.

“…Purpose Antibiotic prophylaxis is standard procedure in transurethral resection of the prostate (TURP). We evaluated the necessity of antibiotic (AB)…”
Get full text

Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD by De Preter, Vicky, Machiels, Kathleen, Joossens, Marie, Arijs, Ingrid, Matthys, Christophe, Vermeire, Severine, Rutgeerts, Paul, Verbeke, Kristin

“…Bacteria play a role in the onset and perpetuation of intestinal inflammation in IBD. Compositional alterations may also change the metabolic capacities of the…”
Get more information

A randomized trial regarding Antimicrobial Prophylaxis (AMP) in Transurethral Resection of Bladder tumor (TURB) in support of antimicrobial stewardship by Baten, E., Van Der Aa, F., Goethuys, H., Slabbaert, K., Arijs, I., Van Renterghem, K.

Get full text

A randomized controlled trial concerning Antimicrobial Prophylaxis (AMP) in Transurethral Resection of Bladder tumor (TURB): Another step forward in antimicrobial stewardship? by Baten, E., Van Der Aa, F., Goethuys, H., Slabbaert, K., Arijs, I., Van Renterghem, K.

Get full text

Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease by Schnitzler, Fabian, Fidder, Herma, Ferrante, Marc, Noman, Maja, Arijs, Ingrid, Van Assche, Gert, Hoffman, Ilse, Van Steen, Kristel, Vermeire, Séverine, Rutgeerts, Paul

“…Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long‐term outcome of IFX…”
Get full text

Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy by White, K., Connor, K., Meylan, M., Bougoüin, A., Salvucci, M., Bielle, F., O’Farrell, A.C., Sweeney, K., Weng, L., Bergers, G., Dicker, P., Ashley, D.M., Lipp, E.S., Low, J.T., Zhao, J., Wen, P., Prins, R., Verreault, M., Idbaih, A., Biswas, A., Prehn, J.H.M., Lambrechts, D., Arijs, I., Lodi, F., Dilcan, G., Lamfers, M., Leenstra, S., Fabro, F., Ntafoulis, I., Kros, J.M., Cryan, J., Brett, F., Quissac, E., Beausang, A., MacNally, S., O’Halloran, P., Clerkin, J., Bacon, O., Kremer, A., Chi Yen, R.T., Varn, F.S., Verhaak, R.G.W., Sautès-Fridman, C., Fridman, W.H., Byrne, A.T.

“…New precision medicine therapies are urgently required for glioblastoma (GBM). However, to date, efforts to subtype patients based on molecular profiles have…”
Get full text

Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC by Machiels, Kathleen, Sabino, João, Vandermosten, Leen, Joossens, Marie, Arijs, Ingrid, de Bruyn, Magali, Eeckhaut, Venessa, Van Assche, Gert, Ferrante, Marc, Verhaegen, Jan, Van Steen, Kristel, Van Immerseel, Filip, Huys, Geert, Verbeke, Kristin, Wolthuis, Albert, de Buck Van Overstraeten, Anthony, D'Hoore, Andre, Rutgeerts, Paul, Vermeire, Séverine

“…Pouchitis is the most common complication after colectomy with ileal pouch-anal anastomosis (IPAA) for UC and the risk is the highest within the 1st year after…”
Get more information

Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment by Arijs, Ingrid, De Hertogh, Gert, Lemaire, Katleen, Quintens, Roel, Van Lommel, Leentje, Van Steen, Kristel, Leemans, Peter, Cleynen, Isabelle, Van Assche, Gert, Vermeire, Séverine, Geboes, Karel, Schuit, Frans, Rutgeerts, Paul

“…Antimicrobial peptides (AMPs) protect the host intestinal mucosa against microorganisms. Abnormal expression of defensins was shown in inflammatory bowel…”
Get full text

P347 Practical recommendations for the collection of the patient-reported outcomes included in the Health Outcomes Observatory (H2O) core data set for patients with inflammatory bowel disease by Fierens, L, Casellas, F, Borruel, N, van der Woude, C J, Huberts, A S, Siegmund, B, Sonnenberg, E, Novacek, G, Gerold, N, Stamm, T, Hedin, C R, Julsgaard, M, Fiorino, G, Radice, S, Zini, M L L, Gross, E, Sander, C, Arijs, I, Vakouftsi, V R, Carney, N, Charlafti, I, Ferrante, M

“…Abstract Background Large scale data integration and comparison require standardised data collection. As part of the Health Outcomes Observatory (H2O) project,…”
Get full text

A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus Process by Fierens, Liselotte, Carney, Nicholas, Novacek, Gottfried, van der Woude, C Janneke, Siegmund, Britta, Casellas, Francesc, Borruel, Natalia, Huberts, Anouk S, Sonnenberg, Elena, Gerold, Nathalie, Primas, Christian, Hedin, Charlotte R H, Stamm, Tanja, Julsgaard, Mette, Fiorino, Gionata, Radice, Simona, Zini, Michela Luciana Luisa, Gross, Evelyn, Sander, Cornelia, Arijs, Ingrid, Vakouftsi, Vasiliki-Rafaela, Koltai, Tunde, Health Outcomes Observatory [H2O] Patient Advisory Board for Inflammatory Bowel Diseases, Health Outcomes Observatory [H2O] Steering Committee, Charlafti, Iliàs, Ferrante, Marc

“…Abstract Background and Aims Standardising health outcome measurements supports delivery of care and enables data-driven learning systems and secondary data…”
Get full text

P005 A multi-marker serum test to assess the presence of ulcerations in infliximab treated patients with Crohn’s disease by de Bruyn, M, Bessissow, T, Kondragunta, V, Jain, A, Arijs, I, Van Assche, G, Ferrante, M, Opdenakker, G, Vermeire, S

“…Abstract Background Resolution of ulcerations is an important component of mucosal healing (MH) in Crohn’s disease (CD) that is typically assessed with…”
Get full text

Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease by Vanhove, Wiebe, Nys, Kris, Arijs, Ingrid, Cleynen, Isabelle, Noben, Manuel, De Schepper, Sebastiaan, Van Assche, Gert, Ferrante, Marc, Vermeire, Séverine

“…Abstract Background Endoplasmic reticulum [ER] stress was shown to be pivotal in the pathogenesis of inflammatory bowel disease. Despite progress in…”
Get full text

P035 TNF-driven pathways are increased at baseline in Crohn's disease patients not responding to infliximab by Verstockt, B., Arijs, I., de Bruyn, M., Verstockt, S., Van Assche, G., Breynaert, C., Vermeire, S., Ferrante, M.

Get full text

P095 The genetic risk in ER stress and autophagy translates into quantifiable epithelial ER stress levels in IBD patients by Vanhove, W., Nys, K., Arijs, I., Cleynen, I., de Bruyn, M., Korf, H., Ferrante, M., Van Assche, G., Vermeire, S.

Get full text

Practical recommendations for the collection of the patient-reported outcomes included in the Health Outcomes Observatory (H2O) core data set for patients with inflammatory bowel disease by Fierens, L, Casellas, F, Borruel, N, van der Woude, CJ, Huberts, AS, Siegmund, B, Sonnenberg, E, Novacek, G, Gerold, N, Stamm, T, Hedin, CR, Julsgaard, M, Fiorino, G, Radice, S, Zini, MLL, Gross, E, Sander, C, Arijs, I, Vakouftsi, VR, Carney, N, Charlafti, I, Ferrante, M

Get full text